Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 224.03M P/E - EPS this Y 47.10% Ern Qtrly Grth -
Income -24.43M Forward P/E -9.21 EPS next Y 50.00% 50D Avg Chg -9.00%
Sales 129.37M PEG -0.10 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book N/A EPS next 5Y 70.00% 52W High Chg -37.00%
Recommedations 2.50 Quick Ratio 1.78 Shares Outstanding 174.37M 52W Low Chg 93.00%
Insider Own 1.43% ROA -11.56% Shares Float 145.96M Beta 0.90
Inst Own 62.30% ROE - Shares Shorted/Prior 3.42M/3.61M Price 1.29
Gross Margin 68.80% Profit Margin -18.88% Avg. Volume 2,107,537 Target Price 4.04
Oper. Margin -15.87% Earnings Date Mar 5 Volume 1,422,371 Change -3.01%
About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Rigel Pharmaceuticals, Inc. News
02/22/24 Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
02/19/24 Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
01/15/24 When Will Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Become Profitable?
01/08/24 Rigel Pharmaceuticals Provides Business Update
01/05/24 Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01/04/24 Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
01/03/24 Here's Why You Should Bet on Rigel Pharmaceuticals (RIGL) Now
01/03/24 Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/02/24 Corcept (CORT) Falls on Loss of Korlym Patent Lawsuit to Teva
01/02/24 Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?
12/18/23 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Catapults 44% Though Its Price And Business Still Lag The Industry
12/12/23 Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders are up 20% this past week, but still in the red over the last three years
12/08/23 Best Momentum Stock to Buy for December 8th
12/08/23 Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
11/22/23 Best Momentum Stocks to Buy for November 22nd
11/22/23 New Strong Buy Stocks for November 22nd
11/08/23 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2023 Earnings Call Transcript
11/07/23 Rigel Pharmaceuticals Inc (RIGL) Reports Q3 2023 Financial Results: A Step Towards Financial ...
11/07/23 Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
11/06/23 Rigel to Present at the Jefferies London Healthcare Conference
RIGL Chatroom

User Image joNANOthan Posted - 5 hours ago

$RIGL Nice article on Gavreto. Sounds like there is a lot of upside potential. https://pharmaphorum.com/news/after-roches-exit-blueprint-passes-gavreto-rigel

User Image adrum Posted - 10 hours ago

@Okonomiyaki should be $RIGL I like this set up. 🕳️🧑‍🦯💥 😂 let’s hope it works out haha

User Image Okonomiyaki Posted - 16 hours ago

$RIGL I like this set up. 🕳️🧑‍🦯

User Image joNANOthan Posted - 1 day ago

$RIGL Okay, this one is very interesting considering Rigel (via Rain) has an MDM2 inhibitor under development. Check this new study out. A new paper by Martinez et al. in the journal eNeuro titled Amyloid-β-induced dendritic spine elimination requires Ca2+-permeable AMPA receptors, AKAP-Calcineurin-NFAT signaling, and the NFAT target gene Mdm2 is fascinating. The paper essentially states that inhibiting MDM2 can stop the destruction of synapses and dendritic spines commonly seen in Alzheimer's disease. Rigel’s collaboration with Daiichi in Japan produced an MDM2 inhibitor that Daiichi sub-licensed to Rain. We have lots of rights around this. Rain is not studying it in Alzheimer’s, but if the target becomes red hot someone will probably buy them. Anyway, you can see the paper here. https://www.eneuro.org/content/early/2024/02/07/ENEURO.0175-23.2024

User Image joNANOthan Posted - 1 day ago

$RIGL Thoughts on Rigel/Annora patent situation. On 10/4/2023 Annora filed a Responsive Claim Construction Brief. In that Brief it states “For “starch,” Annora’s construction reflects the use of that term in the intrinsic evidence, which permits physical modification of starch”. Rigel believes that their patents cover all forms of starch whether physically or chemically modified. The judge Opinion ultimately concludes that the term "starch" includes native starches which have been modified by physical or chemical means. How can Annora possibly reformulate fostamatinib if they can’t change the starch? It's like trying to make pancakes and Rigel owns the batter. This is all just my opinion. I am not a patent expert and have no legal expertise. So take this all with a grain of salt…and make sure to wash it down with some water.

User Image GO_DAWGS Posted - 1 day ago

$RIGL still no CMO?

User Image starstx Posted - 2 days ago

$RIGL Is this the year? I have laughed, cursed, cried, groaned, jumped for joy and everything in between ... but is this the year we FINALLY break $2.00 and then down the road see 3.00 to 5.00 ... I habe been rooting for this one forever!

User Image tobeme100 Posted - 2 days ago

$RIGL EPS current estimated -.02 for 2023(Q4). IMO could be better or even +. ER may be due next week.

User Image B4I4QQTRU18 Posted - 2 days ago

$RIGL https://seekingalpha.com/article/4672556-rigel-pharmaceuticals-upgrade-top-idea-ahead-of-q42023?mailingid=34456980&messageid=must_reads&serial=34456980.1624693&utm_campaign=email_mr%3Aevergreen_lp_premium_test_eligible_feb2024%2B2024-02-23&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads_free_eligible

User Image DBales26 Posted - 2 days ago

$RIGL

User Image B4I4QQTRU18 Posted - 2 days ago

$RIGL thank you👇

User Image B4I4QQTRU18 Posted - 2 days ago

$RIGL come on. Give us a couple Pennies today, so someone can drop it a nickel after hours with 1 share. 🤣

User Image DBales26 Posted - 2 days ago

$RIGL Sorry for the duplicate posts. ST was acting up and post was not working right away :)

User Image DBales26 Posted - 2 days ago

$RIGL I wouldn't be shocked by this. From @Berakhot's post about LXRX, since Lilly plays hardball, which we've seen with Point Biopharma and that acquisition. I actually went from thinking Lilly was going to acquire Rigel to now Rigel fighting them off after Gavreto rights were acquired, since clearly Lilly was trying to get them on the cheap with the Fost patent lawsuit ongoing and Rigel not reaching profitability yet. Good thing both of those could be on the near horizon. Rigel clearly wants to remain independent and grow, but perhaps get acquired much further down the road. I'm fine with this since Raul and Santos seem to have the business development and sales/marketing skills and expertise to grow this company. Whoever is working with Lilly or with Rigel (Armistice, Soleus, Morgan Stanley), it doesn't really matter because once we hit profitability (hopefully a couple weeks) and the Fost patent lawsuit ends, nothing will be able to stop true market nature.

User Image DBales26 Posted - 2 days ago

$RIGL I wouldn't be shocked by this since Lilly plays hardball, which we've seen with Point Biopharma and that acquisition. I actually went from thinking Lilly was going to acquire Rigel to now Rigel fighting them off, since clearly Lilly was trying to get them on the cheap with the Fost patent lawsuit ongoing and Rigel not reaching profitability yet. Good thing both of those could be on the near horizon. Rigel clearly wants to remain independent and grow, but perhaps get acquired much further down the road (2025-2026 and beyond). I'm fine with this since Raul and Santos seem to have the business development and sales/marketing skills and expertise to grow this company. Whoever is working with Lilly or with Rigel (Armistice, Soleus, Morgan Stanley), it doesn't really matter because once we hit profitability (hopefully a couple weeks) and the Fost patent lawsuit ends, nothing will be able to stop true market nature.

User Image MSUalum Posted - 2 days ago

$RIGL Rual working hard to redeem himself.

User Image Namhguab Posted - 2 days ago

$RIGL picked up more on that small dip this morning. Lets go!

User Image YearOfTheRabbit Posted - 2 days ago

$RIGL they are back, actually never left

User Image mitgodog Posted - 2 days ago

$RIGL let's see how far down they plan on driving the price today??

User Image Thestocktraderhubzee Posted - 3 days ago

WATCHLIST FEB 23 2024.. $LKQ Barrington Research Reiterates Outperform on LKQ, Maintains $60 Price Target $RIGL HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target $DASH Morgan Stanley Upgrades DoorDash to Overweight, Raises Price Target to $145 $SNOW UBS Maintains Neutral on Snowflake, Raises Price Target to $225 $LCID B of A Securities Maintains Neutral on Lucid Gr, Lowers Price Target to $4.5

User Image Berakhot Posted - 3 days ago

$RIGL LXRX... the tricks of the trade are widespread. As we focus attention on Rigel being shorted, etc., it happens all over the market in similar ways and methods. Just thought I'd share with all the longs and hope some of you picked up more under 1.30 or played the options...

User Image B4I4QQTRU18 Posted - 3 days ago

$RIGL Actually Gavreto was approved August 9th 2023, so 28 million last year projects to 50+ million if I am thinking correctly. This is great if true.

User Image B4I4QQTRU18 Posted - 3 days ago

$RIGL Looks like a decent deal. They should get is on the steal somewhat. 10 mil on first Sale ~ 3Q and another 5 mil about a year from now. It sold 28 million last year. They do have some royalties to pay, but if there current overhead can handle most of the lifting here, then this should pan out. Seems they paid 20 mil for Rez and it's only earning ~ 5-10 mil/year. They did get WW rights to Rez, but with those sales it's not something OUS partners are jumping to get their hands on. I guessing Blueprint was hoping for just about anything with Roche/Genentech telling them to pound sand. Santos, get to work and steal some of that 200 + sales from Lilly. Hypothetically that could put them at ~175 million per year. 120 Fost, 40 Gav, 15 Rez. Definately should solidify CF+.

User Image meistermell Posted - 3 days ago

$RIGL when lambo? Few years? lol

User Image noproetu Posted - 3 days ago

$RIGL plot twist . RIGL offers buyout to acquire LLY!

User Image tobeme100 Posted - 3 days ago

$RIGL With the exclusive right to US market, I think RIGL can further explore the potential of Gavreto across multiple RET-altered tumour types. Any objection?

User Image MisterWinston Posted - 3 days ago

$RIGL How about some green candles in AH.

User Image tobeme100 Posted - 3 days ago

$RIGL Roche still have the right to GAVRETO outside of the US.

User Image Cloud875 Posted - 3 days ago

$RIGL closing at the high, let’s open at $1.50 tomorrow

User Image Gabriel1234 Posted - 3 days ago

$RIGL https://www.investing.com/equities/rigel-pharmaceuticals-technical

Analyst Ratings
HC Wainwright & Co. Buy Feb 22, 24
HC Wainwright & Co. Buy Jan 4, 24
HC Wainwright & Co. Buy Dec 8, 23
HC Wainwright & Co. Buy Aug 2, 23
HC Wainwright & Co. Buy May 3, 23
Citigroup Buy Mar 9, 23
HC Wainwright & Co. Buy Mar 8, 23
Citigroup Buy Dec 2, 22
BMO Capital Outperform Nov 4, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Santos David A EVP, Chief Commercia.. EVP, Chief Commercial Officer Feb 02 Sell 1.14 14,519 16,552 349,093 02/06/24
Schorno Dean L EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Sell 1.13 12,628 14,270 402,891 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Feb 02 Sell 1.14 52,894 60,299 2,036,629 02/06/24
RODRIGUEZ RAUL R CEO, President CEO, President Jun 09 Buy 0.6884 1,000,000 688,400 1,391,776 06/13/22